Siergiejko Z, Obrzut D, Rogalewska A
Kliniki Alergologii AM, Białymstoku.
Pol Tyg Lek. 1991;46(22-23):424-7.
Ambroxol (Bronchopront-Mack) was administered to 73 patients with the bronchial asthma and spastic bronchitis with expectoration disorders. The drug was given in the dosage forms of slow release capsules, syrup, drops, intramuscular injections and inhalations for about 14 days. All patients have been carefully examined clinically, PEF has been measured, and sputum physico-chemical properties have been tested prior to and 10 days after treatment. Complete disappearance of cough, liquefaction of sputum and clearance of airways have been achieved in 47% of patients. A significant improvement has been noted in 38.4% of cases. The treatment failed in 2.7% of patients. Ambroxol has been well tolerated. No adverse effects on laboratory findings have been noted. Results suggest, that ambroxol is valuable drug in the combined treatment of patients with the bronchial asthma and spastic bronchitis.
氨溴索（沐舒坦-Mack）用于治疗73例患有支气管哮喘和痉挛性支气管炎且伴有咳痰障碍的患者。该药物以缓释胶囊、糖浆、滴剂、肌肉注射剂和吸入剂等剂型给药，疗程约14天。所有患者均接受了仔细的临床检查，测量了呼气峰流速（PEF），并在治疗前及治疗10天后检测了痰液的理化性质。47%的患者咳嗽完全消失，痰液液化，气道通畅。38.4%的病例有显著改善。2.7%的患者治疗失败。氨溴索耐受性良好。未观察到对实验室检查结果的不良影响。结果表明，氨溴索是支气管哮喘和痉挛性支气管炎患者联合治疗中的一种有价值的药物。
